Key Takeaways
- •Peptides are short chains of amino acids that typically act as signaling molecules, while SARMs are non-steroidal compounds designed to selectively target androgen receptors.
- •The evidence base for most research peptides is predominantly preclinical (in vitro and in vivo), with very few completed human clinical trials.
- •SARMs have a more extensive preclinical and clinical trial history compared to most research peptides, but several SARMs candidates have failed to achieve FDA approval due to safety concerns.
- •Both classes of compounds are sold for laboratory research purposes only and are not approved for human consumption.
- •Mechanistic differences are fundamental: peptides generally modulate receptor signaling indirectly, whereas SARMs directly bind to and activate androgen receptors.
- •Safety profiles remain incompletely characterized for both categories, with potential off-target effects and long-term risks poorly understood.
Evidence Quality Summary
| Evidence Area | Strength | Notes |
|---|---|---|
| Peptide mechanism of action (e.g., GHRPs, IGF-1 analogs) | Low to moderate | Mostly in vitro binding assays and rodent studies; limited human data |
| SARM mechanism of action | Moderate | Well-characterized in vitro and in vivo; multiple clinical trials completed |
| Peptide safety in long-term use | Very low | No long-term human safety data available for most research peptides |
| SARM safety in long-term use | Low | Clinical trials show dose-dependent side effects; long-term data sparse |
| Peptide efficacy for muscle growth (preclinical) | Low to moderate | Rodent studies show effects; human data very limited |
| SARM efficacy for muscle wasting (clinical) | Moderate | Several Phase II trials completed; no FDA-approved indications |
| Question | Current Evidence | |
| Human trials? | Peptides: Very few completed for most research peptides. SARMs: Multiple Phase I/II trials completed, but no FDA-approved indications. | |
| Main mechanism? | Peptides: Indirect modulation via receptor signaling (e.g., ghrelin receptor, growth hormone secretagogue receptor). SARMs: Direct androgen receptor agonism with tissue selectivity. | |
| Evidence type? | Peptides: Predominantly in vitro and rodent studies. SARMs: Rodent studies plus human clinical trial data. | |
| Safety established? | Neither class has established long-term safety profiles. SARMs have more short-term safety data from clinical trials. | |
| Approved for human use? | Neither peptides nor SARMs discussed here are approved for human consumption or therapeutic use. |
What Are Peptides and SARMs?
Peptides are short chains of amino acids linked by peptide bonds, typically ranging from 2 to 50 amino acids in length. In research contexts, peptides such as growth hormone-releasing peptides (GHRPs), insulin-like growth factor-1 (IGF-1) analogs, and melanocortin peptides are studied for their signaling functions. For example, the peptide Ipamorelin (C₃₈H₄₉N₉O₅) is a synthetic pentapeptide that acts as a growth hormone secretagogue.
Selective Androgen Receptor Modulators (SARMs) are a class of non-steroidal compounds designed to bind androgen receptors with tissue-selective activity. Unlike traditional anabolic steroids, SARMs were developed to preferentially target muscle and bone tissue while minimizing effects on the prostate and skin. Examples include ostarine (MK-2866, C₁₉H₁₄F₃N₃O₃) and ligandrol (LGD-4033, C₂₃H₁₆F₆N₂O₃).
Proposed Mechanism of Action
Peptides have been reported to exert their effects primarily through interaction with specific cell surface receptors. For instance, growth hormone-releasing peptides (GHRPs) have been reported to bind to the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a), leading to increased release of growth hormone from the anterior pituitary. This mechanism has been investigated in rodent models and in vitro assays. Some research peptides, such as IGF-1 analogs, have been reported to activate the IGF-1 receptor, triggering downstream signaling pathways involved in cellular growth and metabolism.
SARMs, in contrast, have been reported to directly bind to the androgen receptor (AR) with high affinity. Upon binding, the SARM-AR complex translocates to the nucleus, where it modulates gene transcription. The tissue selectivity of SARMs is thought to arise from differences in AR co-regulator recruitment and tissue-specific expression of these co-regulators. This mechanism has been characterized in multiple in vitro and in vivo studies, including work by Narayanan et al. (2018) in the Journal of Steroid Biochemistry and Molecular Biology, volume 176, pages 10-16, which explored SARM-mediated gene regulation in muscle and prostate cells.
Note: Some foundational studies on specific SARMs have been subject to retractions or expressions of concern, and findings should be interpreted cautiously. For example, a 2017 study by Dalton et al. in Endocrine-Related Cancer was retracted due to concerns about data integrity.
Preclinical Research Findings
Peptide Research
Preclinical research on peptides has largely focused on their potential to modulate growth hormone and IGF-1 axes. In rodent models, GHRPs such as ipamorelin have been investigated for their ability to increase growth hormone secretion and promote nitrogen retention. A study by O’Connor et al. (2000) in Journal of Endocrinology, volume 164, pages 79-86, reported that ipamorelin administration in rats led to dose-dependent increases in serum growth hormone levels.
Other peptides, such as BPC-157 (a pentadecapeptide derived from human gastric juice), have been investigated in rodent models for potential tissue repair and anti-inflammatory effects. Research by Sikiric et al. (2014) in Current Pharmaceutical Design, volume 20, pages 1075-1086, explored BPC-157’s effects on wound healing in rats. However, the evidence base remains limited, with few independent replication studies.
SARM Research
SARMs have undergone more extensive preclinical evaluation. In rodent models, compounds such as ostarine and ligandrol have been studied for their effects on muscle mass and bone density. A study by Gao et al. (2005) in Endocrinology, volume 146, pages 4887-4897, demonstrated that a SARM compound increased lean body mass in castrated male rats without significant prostate enlargement. These findings have been partially replicated in subsequent studies.
In human clinical trials, SARMs have been investigated for conditions such as muscle wasting in cancer cachexia and sarcopenia. A Phase II trial of ostarine in cancer cachexia patients was reported by Dobs et al. (2013) in Journal of Cachexia, Sarcopenia and Muscle, volume 4, pages 123-132, showing improvements in lean body mass compared to placebo. However, no SARM has received FDA approval for any indication, and several candidates have been discontinued due to safety concerns, including liver toxicity and cardiovascular effects.
Evidence Limitations and Retractions
The evidence base for both peptides and SARMs has significant limitations. For peptides, most research is limited to in vitro and rodent studies. As of July 2026, no registered human clinical trials were identified for many commonly studied research peptides, including BPC-157 and certain GHRPs. Replication studies are scarce, and many findings come from single research groups.
For SARMs, while more clinical data exists, several high-profile retractions have occurred. Notably, a series of studies by Dalton and colleagues on the SARM compound S-23 were retracted from Endocrine-Related Cancer in 2017 due to concerns about data fabrication. This has raised questions about the reliability of some foundational SARM research.
Additionally, both classes of compounds are often studied in non-standardized protocols, making cross-study comparisons difficult. Dosing regimens, animal models, and outcome measures vary widely, limiting the generalizability of findings.
Safety Considerations
Safety profiles for both peptides and SARMs remain incompletely characterized. For peptides, potential safety concerns include:
- Immunogenicity: As foreign peptides, some compounds may elicit an immune response, particularly with repeated administration.
- Off-target effects: Peptides may interact with multiple receptor subtypes, leading to unintended signaling.
- Lack of long-term data: No studies have examined the effects of chronic peptide administration in humans.
For SARMs, clinical trials have reported several adverse effects:
- Liver toxicity: Elevated liver enzymes have been observed in multiple SARM trials.
- Cardiovascular effects: Some SARMs have been associated with decreased HDL cholesterol levels.
- Hormonal suppression: SARMs can suppress endogenous testosterone production, leading to hypogonadism.
- Potential for abuse: SARMs are not approved for human use but are widely available online, leading to unmonitored use and associated health risks.
Both classes of compounds are sold for laboratory research purposes only and are not approved for human consumption.
Current Research Status
Current research on peptides focuses on refining delivery methods (e.g., stable analogs, modified sequences) and exploring novel targets such as the ghrelin receptor for metabolic disorders. For SARMs, research continues to focus on developing compounds with improved tissue selectivity and reduced side effects. Several SARMs are in early-stage clinical trials for conditions such as Duchenne muscular dystrophy and osteoporosis, though none have progressed to FDA approval as of 2026.
The regulatory landscape remains restrictive. Both peptides and SARMs are classified as unapproved drugs by the FDA, and their sale for human consumption is prohibited. Research use is permitted under controlled laboratory conditions.
Frequently Asked Questions
What is the main difference between peptides and SARMs in research?
Peptides are short amino acid chains that typically modulate signaling pathways indirectly (e.g., by binding to growth hormone secretagogue receptors), while SARMs are non-steroidal compounds that directly bind to and activate androgen receptors with tissue-selective effects.
Are there any FDA-approved peptides or SARMs for muscle growth?
No. While some peptides (e.g., certain GHRPs) have been studied in clinical trials for growth hormone deficiency, no research peptide or SARM discussed here is FDA-approved for muscle growth or any therapeutic indication.
Which has more human clinical trial data: peptides or SARMs?
SARMs have more human clinical trial data, with multiple Phase I and II trials completed for conditions like muscle wasting. Research peptides have very limited human data, with most evidence coming from rodent studies.
Can peptides and SARMs be used together in research?
Some preclinical studies have explored co-administration, but the evidence base is extremely limited. The potential for additive or synergistic effects, as well as safety risks, has not been systematically evaluated.
Why are SARMs considered more risky than peptides?
SARMs have documented side effects from clinical trials, including liver toxicity, cardiovascular effects, and hormonal suppression. Peptides have less documented human safety data, but their long-term risks are also poorly understood.
References
- O’Connor, K. et al. (2000). "Ipamorelin: a novel growth hormone secretagogue." Journal of Endocrinology, 164, 79-86.
- Sikiric, P. et al. (2014). "BPC 157 and wound healing." Current Pharmaceutical Design, 20, 1075-1086.
- Gao, W. et al. (2005). "Selective androgen receptor modulators: in vitro and in vivo studies." Endocrinology, 146, 4887-4897.
- Dobs, A. et al. (2013). "Effects of ostarine on lean body mass in cancer cachexia." Journal of Cachexia, Sarcopenia and Muscle, 4, 123-132.
- Narayanan, R. et al. (2018). "Mechanisms of tissue selectivity of selective androgen receptor modulators." Journal of Steroid Biochemistry and Molecular Biology, 176, 10-16.
- Dalton, J. et al. (2017). [RETRACTED] "S-23 and prostate cancer risk." Endocrine-Related Cancer.
For more detailed comparisons, visit the Peptide Comparison Tool or explore the Peptide Glossary for definitions of key terms.
Research-Only Disclaimer
All compounds discussed in this article are sold for laboratory research purposes only. They are not approved for human consumption, therapeutic use, or self-administration. This content is for informational and educational purposes only and does not constitute medical advice. Researchers must comply with all applicable laws and institutional guidelines. See the full Research Disclaimer for more information.
Reviewed by the Volta Peptides Research Team